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INTRODUCTION
Slamon et al. (1) first described the association of an ampli-
fication of the HER-2/neu gene with an unfavorable outcome
in breast cancer in 1987. The HER-2/neu oncogene, which
is located on chromosome 17q21, is homologous with, but
distinct from, the epidermal growth factor receptor and en-
codes for a 185-kDa transmembrane glycoprotein that possesses
intracellular tyrosine kinase activity (1-6). This gene is ampli-
fied and overexpressed in approximately 20-40% of breast
cancers (1-7). Amplification and overexpression of the HER-
2/neu oncogene correlates with a more aggressive disease as
shown by the association with a shorter disease-free and over-
all survival of women with this alteration (1, 2, 4-6). HER-
2/neu amplification and overexpression has been correlated
with the responsiveness to adriamycin chemotherapy in addi-
tion to a lack of a responsiveness to tamoxifen therapy (7-9).
The clinical importance of the HER-2/neu diagnostics has
risen even more with the increasing use of the new anti-can-
cer drug, trastuzumab (Herceptin, Roche Ltd. Basel, Switzer-
land), a humanized monoclonal antibody to the extracellular
domain of HER-2/neu oncoprotein, to treat metastatic breast
carcinoma (2, 10-12). 
Because of the heightened interest in selecting patients for
both adjuvant treatment and Herceptin treatment based on
the alterations in the HER-2/neu oncogene, considerable atten-
tion has been focused on the accuracy of the clinical assays
used to evaluate the level of HER-2/neu amplification and
overexpression. Most studies of the HER-2/neu oncogene in
breast cancer have used immunohistochemistry (IHC) to
evaluate its overexpression. IHC is relatively inexpensive and
easy to perform but has a number of shortcomings. The inter-
pretation of IHC is subjective and has been found to vary
among observers (13, 14). Fluorescent in situ hybridization
(FISH) assays have been used to evaluate the level of gene
amplification in paraffin-embedded specimens. These assays
are more complicated to perform than IHC and require flu-
orescence microscopy (15, 16). Chronogenic in situ hytridi-
gation (CISH) was investigated as a new modification and an
extremely accurate and sensitive technique, in which a chro-
mosomal DNA probe is detected using an immunohistochem-
ical-like peroxidase reaction (17). CISH offers three important
advantages; 1) the histological details of the paraffin section
are generally better appreciated with a bright field, 2) the
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HER-2/neu Oncogene Amplification by Chromogenic in situ 
Hybridization in 130 Breast Cancers Using Tissue Microarray and
Clinical Follow-up Studies
Determining of HER-2/neu oncogene amplification has become clinically important
for managing breast cancer. Fluorescent in situ hybridization (FISH) and immuno-
histochemistry (IHC) are currently regarded as the standard methods. Chromogenic
in situ hybridization (CISH) was investigated as a new modification with an accurate,
sensitive technique. From 1998 to 2002, using CISH and IHC, the amplification and
protein expression of the HER-2/neu oncogene were examined using paraffin sec-
tions in 130 breast carcinomas and to determine the prognostic role of HER-2/neu
for outcome after a follow-up of 24- 64 months. Amplifications by CISH and overex-
pression by IHC were observed in 28 (22%) and 27 cases (20.8%), respectively. Of
the 104 patients, 20 patients (19.2%) with amplification had a shorter disease-free
interval (34.9 months vs. 38.0 months in controls) (p=0.372). 15 patients (14.4%)
had a disease recurrence, but there is no significant difference between 3 patients
amplifying the oncogene and 12 patients without oncogene (20.6 months vs. 19.6
months) (p=0.862). 6 patients (5.8%) of these died. CISH is a useful alternative,
particularly for confirming the IHC results. There is no relationship between the early
recurrence and the HER-2/neu positive group, but lymph node status was statisti-
cally significant.
Key Words : Breast Neoplasms; Receptor, erbB-2; In Situ Hybridization; Immunohistochemistry; Pro-
tein Array Analysis
Received : 18 November 2003
Accepted : 16 January 2004HER-2/neu Amplification by CISH 391
morphological details are readily apparent using low-power
objectives, and 3) the probe signals are not subject to rapid
fading (17-19). However, CISH analysis has not been exten-
sively studied in breast cancer specimens in contrast to FISH
analysis. Therefore, in this study, we analyzed the level of HER-
2/neu gene amplification using CISH, and we correlated the
findings with IHC in 130 breast cancers specimens obtained
from operable patients. And also this study attempted to deter-
mine the predictive role of HER-2/neu for the disease-free in-
terval after a follow-up of 24- 64 months (mean=40.0 months)
in 104 patients.
MATERIALS AND METHODS
From 1998 to 2002, 130 consecutive patients with breast
cancer were tested for the overexpression of the cell surface
oncoprotein by IHC (Novocastra Laboratories, Newcastle,
U.K.) and amplification of the HER-2/neu oncogene by CISH
(SPOT-LIGHT, Zymed, South San Francisco, CA, U.S.A.).
All patients had tissue samples that were initially tested for
the HER-2/neu gene product by IHC, which were interpreted
independently by three pathologists. The findings with scores
of 2+ to 3+ by IHC were considered to be immunopositive
(17, 20). If the results were positive, anthracycline-based therapy
was given. Because of the possibility of false positive or neg-
ative results by IHC, CISH was performed on all samples.
Tissue microarrays
In order to evaluate significant numbers of the tumors, low-
density tissue microarrays (TMA) blocks were made at the
hospital. The integration of the TMA blocks enabled a high-
throughput determination of the level of HER-2/neu ampli-
fication with rapidity in large cohorts (21, 22). One block
contained 20 cores (single core per tumor), each measuring
3 mm in diameter. Four  m sections were mounted onto the
positively charged slides. 
Chromogenic in situ hybridization
A digoxigenin-labeled genomic probe for HER-2/neu was
obtained from Zymed (South San Francisco, U.S.A.) and used
in CISH, using reagent kits from the same manufacturer. In
brief, the sections were deparaffinized and incubated in pre-
treatment buffer in a temperature-controlled microwave oven
(92℃ for 15 min). Enzymatic digestion was carried out with
pepsin (at room temperature for 10-30 min). The slides were
washed with PBS and dehydrated in graded dilutions of et-
hanol. The HER-2/neu probe (5-10  L/slide) was applied to
the slides under coverslips. The slides were co-denatured on
a hot plate (94℃for 3 min), followed by overnight hybridiza-
tion at 37℃. The slides were washed (0.5× SSC for 5 min),
and the hybridized probe was detected using the CISH detec-
tion reagents (anti-digoxigenin-FITC, anti-FITC-peroxidase,
and diaminobenzidine as chromogen), according to the man-
ufacturer’s instructions. The sections were counterstained with
hematoxylin and mounted. The slides were analyzed by 3 of
us using an ordinary transmitted light microscope under 20×
objective. Generally, 1-4 copies were considered as no ampli-
fication, 5-8 as low-level amplification and >8 gene copies
as high-level amplification (23). Amplification was defined
when greater than 5-10 discrete copies per nucleus or large
gene copy clusters in at least 50% of cancer cells were seen,
as described by Tanner et al. (15). 
Immunohistochemistry
Deparaffinized tissue sections were heat pretreated in sodi-
um citrate buffer (pH 7.3, at 92℃ for 20 min in a temper-
ature-controlled microwave oven) and immunostained with
a labeled monoclonal antibody to the intracellular domain of
HER-2/neu protein (CB-11; Novocastra Laboratories, New-
castle, U.K.). A standard avidin-biotin-peroxidase complex
(ABC) technique was used for visualization, with diaminoben-
zidine as the chromogen (Histostain Plus-kit; Zymed). There
are several methods of interpreting cells stained by IHC. The
most common scoring system is recommended in the Hercep
Test manufacturer’s protocol (24), but this has practical dif-
ficulties and is opened to interpretation errors, particularly
around the subjective IHC 2+/ 3+cutoff point. DAKO (the
manufacturer of the Hercep Test) have recently modified their
recommendations and propose FISH testing of all IHC 2+
tumors (24). The Finnish and Swedish guidelines advocate
retesting all IHC 2+ and 3+ samples by in situ hybridiza-
tion, diminishing the need to make a distinction between these
two groups (25). Because the concordance between IHC at the
2+level and FISH can be as low as 25% and the concordance
between IHC 3+ and FISH is around 90% (25-28), only an
intense cell membrane immunoreaction present in >50% of
cancer cells (IHC 3+) was considered as overexpression of
HER-2 protein (25, 29) (Fig. 1).
Statistical analysis
Statistical analysis was performed using SPSS for Windows
(Version 10.0; SPSS, Chicago, IL. U.S.A.). Test-retest reliabil-
ity was assessed using Spearman correlation. Comparison of
survival between two groups was made by independent-sam-
ples t test. Statistical significance for variables, age, tumor size,
lymph node status and HER-2/neu amplification by CISH
and survival was examined using the multivariate test. A p-
value of <0.05 was considered significant.
RESULTS
Amplification was seen most often as large gene copy clus-392 E. Chang, A. Lee, E. Lee, et al.
ters in the majority of nuclei (Fig. 2). Of the 130 breast car-
cinomas, amplifications of the HER-2/neu oncogene by CISH
were observed in 28 cases (22%), and the HER-2/neu protein
overexpression was identified by IHC in 27 cases (20.8%)
(concordance rate: 94.96%) (Table 1). The tumors from 15
(11.5%) patients showed both amplification and overexpres-
sion, while 12 (9.2%) tumors displayed overexpression with-
out amplification and 3 (2.3%) tumors displayed amplifica-
tion without overexpression. Non-amplified tumors showed
1 to 3 clearly defined dots in the nucleus (Fig. 3).
Correlation between clinicopathologic variables and 
survival rate 
Twenty-six patients were excluded from outcome analysis
because of a short follow-up time (less than 2 yr). The remain-
ing 104 patients were analyzed for disease-free survival. The
mean follow-up period was 40.0 months. Of the 104 patients,
20 patients (19.2%) with oncogene amplification had a shorter
median disease-free survival (34.9 months) compared to the
controls (38.0 months), but statistically insignificant (p=0.871)
(Table 2). There is no relationship between the early recurrence
(shortened disease-free interval) and patient’s age and tumor
size, but lymph node status was statistically significant (p=
0.010). Of the 104 patients, 15 patients (14.4%) had a dis-
Fig. 1. Immunohistochemical staining for HER-2/neu oncogene
shows strong, complete membrane staining (score 3+), ×200.
Fig. 3. No amplification by chromogenic in situ hybridization shows
one to two clearly identifiable copies of HER-2/neu gene. Counter-
stained with hematoxylin, ×200.
Fig. 2. A typical high-level HER-2/neu amplification appears mul-
tiple large clusters of gene copies by chromogenic in situ hybridiza-
tion. Counterstained with hematoxylin, ×200.
*Concordance Rate: 95%.
*Correlation is significant at the .01 level (2-tailed) by Spearman.







IHC score  0 47 2 49 (95.9%)
1 25 1 26 (96.2%)
2 18 10 28 (64.3%)
3 12 15 27 (55.6%)
Total 102 28 130
Table 1. Correlation between amplification by CISH and overex-
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ease recurrence, and 6 patients (5.8%) of these died of mul-
tifocal metastases. 
Clinicopathologic findings of recurred patients 
Clinicopthological characteristics of 15 recurred patients
were shown in Table 3. The mean age at the time of initial
diagnosis was 46.3 yr (range: 31-65 yr) and mean tumor size
was 3.8 cm (range: 1.0-9.0 cm). All patients were diagnosed
as infiltrating ductal carcinoma, and some of them were asso-
ciated with apocrine carcinoma, micropapillary, papillary, duc-
tal carcinoma in situ and Paget’s disease. All cases except one
were observed evidence of lymph node metastases. 6 cases
(40%) metastasized to the bone, and also lung, subclavian
lymph node, thyroid and brain metastases were found. A mean
disease-free survival between 3 patients amplifying the onco-
gene (20.6 months) and 12 patients without oncogene (19.6
months) revealed insignificant difference (p=0.862). 
Surgery and adjuvant therapy
Thirty-six patients (27.7%) and 94 patients (72.3%) were
treated by lumpectomy with axillary node dissection and
modified radical mastectomy, respectively. The patients also
received adjuvant therapy depending on the type of surgery
and nodal status. Breast irradiation was systematically per-
formed in 44 patients, but the chest wall irradiation was per-
formed only on 2 patients with positive axillary nodes that
were treated with a mastectomy. One hundred and five of the
130 patients (80.7%) received adjuvant chemotherapy after
surgery. Twenty patients were given tamoxifen alone (18 neg-
ative for HER-2/neu and 2 positive by CISH) and 85 patients
were given systemic chemotherapy (65 negative for HER-2/
neu and 20 positive by CISH), consisting either of CMF (cy-
clophosphamide, methotrexate, 5-fluorouracil) or FAC (5-flu-
orouracil, adriamycin, cyclophosphamide). Sixty patients
received doxorubicin-based regimens, of whom 46 tested neg-
ative for the HER-2/neu oncogene, and 14 tested positive by
CISH. If the results were positive (2+ or 3+) by IHC, anthra-
cycline-based adjuvant chemotherapy was performed in our
patients. Because IHC 3+ was considered as overexpression
of HER-2 protein, some differences between the number of
doxorubicin-treated patients and case number of overexpres-
sion (IHC 3+).
DISCUSSION
HER-2/neu amplification must occur very early in the genet-
ic cascade, at least before the dissemination of the cancerous
cells (3, 7, 30). The patients with HER-2/neu positivity have
a poor prognosis, including a shortened disease-free survival
and overall survival, in contrast to HER-2/neu negative pa-
tients (6, 12). Previous studies have shown that HER-2/neu
overexpression is significantly associated with an increased Pos., positive; neg., negative.
Variables No. of cases p value
Age n=104 0.538
Tumor size n=104 0.518
Lymph nodes pos. (n=51), neg. (n=53)  0.010
HER-2/neu pos. (n=20), neg. (n=84) 0.871
Table 2. Multivariate analysis of age, tumor size, lymph nodes
and HER-2/neu oncogene amplification by CISH for survival rate
in 104 follow-up cases
Case IHC CISH Size (cm) Diagnosis FU (DFS)(ms.) LN Age (yr)
1 65 + - 2.8×2.5 IFD 3, Apoca 15/18 SCL meta (51 m)
2 51 - - 3.0×2.0 IFD 1, mp 8/9 Lung meta (25 m)
3 33 +++ - 7.1×5.0 IFD 3 16/37 Rib meta (15 m), D
4 42 +++ + 3.5×2.0 IFD 3, Apoca 18/20 Thyroid meta (15 m), D
5 65 - - 3.5×3.0 IFD 1, pp 4/15 D (18 m)
6 52 + - 1.6×1.2 IFD 2 2/14 Lung meta (28 m), D
7 52 +++ + 1.0×1.0 IFD 2, DCIS, Paget’s d 2/14 SCL meta (29 m)
8 44 +++ - 9.0×3.5 IFD 3 30/39 Bone meta (16 m)
9 42 - - 4.7×4.0 IFD 3 10/25 Bone meta (23 m)
10 31 - - 4.0×2.8 IFD 1 1/4 Recur (14 m), Brain meta (25 m), D
11 35 + - 3.0×1.6 IFD 1 1/27 Cervical bone meta (15 m)
12 49 - - 2.0×2.0 IFD 3 43/46 Multiple meta (18 m), D
13 64 - - 4.5×2.5 IFD 1 13/30 Bone meta (6 m)
14 35 ++ + 3.5×2.0 IFD 3, DCIS 1/31 Lung, spine meta (18 m)
15 35 + - 4.5×2.5 IFD 3 0/22 Lung meta (7 m)
Table 3. Clinicopatholigical characteristics and follow-up of 15 recurred patients
*IHC, HER-2/neu overexpression by immunohistochemistry; CISH, HER-2/neu amplification by chromogenic in situ hybridization; Size, Tumor size; LN,
Lymph node metastases (number of metastatic node/number of dissected node); FU, Follow-ups; DFS ms., Disease-free survival months; IFD 1, 2 &
3, Infiltrating ductal carcinoma, grade 1, 2 & 3; Apoca, Apocrine carcinoma; mp, micropapillary type; pp, papillary type; DCIS, Ductal carcinoma in situ;
Paget’s d, Paget’s disease; SCL, Subclavian lymph node; meta, metastasis; D, Died.394 E. Chang, A. Lee, E. Lee, et al.
risk of an earlier relapse and death (6, 31, 32). However, other
studies have not demonstrated this relationship (14). There
is no consensus in the literature concerning the clinical sig-
nificance of the amplification of this oncogene. In this study,
patients with an oncogene amplification had a shorter medi-
an disease-free interval (34.9 months) compared to the con-
trols (38.0 months), but statistically insignificant (p=0.871).
Of the 15 recurred patients, a mean disease-free survival be-
tween 3 patients amplifying the oncogene (20.6 months) and
12 patients without oncogene (19.6 months) revealed insignif-
icant difference (p=0.862). This study suggests there is no
relationship between the early recurrence (shortened disease-
free interval) and the HER-2/neu positive group. No associa-
tion was found between the gene amplification and the tumor
grade, the ER/PR status, or the lymph node status (6). But,
this study revealed that correlation between survival rate and
lymph node status was statistically significant. HER-2/neu
status should not be used to determine whether or not a wo-
man should receive adjuvant systemic therapy and whether
or not a patient should receive endocrine therapy (3, 33). Riou
et al. (4) showed that HER-2/neu amplification had a similar
prognostic value on patients regardless of whether they rece-
ived these treatments or not. If a specific patient’s tumor over-
expresses HER-2/neu and adjuvant chemotherapy is recom-
mended, an anthracycline-containing regimen may be prefer-
able. In contrast, for women whose tumors do not overexpress
HER-2/neu, adjuvant therapy with either a CMF-like or anthra-
cycline-containing regimen appears to be similar (5). Herceptin
therapy is effective only in the HER-2/neu positive patients
and produces a significant survival benefit in patients with
HER-2/neu positive metastatic breast cancer (2, 3, 12, 33).
There are several methods for determining the HER-2/neu
status. IHC is widely available and most laboratories have
experience using this technique. Furthermore, this technique
is quite reliable when performed by experienced laboratories
following established protocols (20). However, previous re-
ports, and U.S. Food and Drug Administration-approved IHC
assay have shown that the method and reproducibility of IHC
for determining the HER-2/neu gene product was inaccurate
in identifying women who are likely to respond to treatment
with Herceptin (6, 24, 34). A deterioration of the antigenicity
over time is causative (4, 20). The factors that can lead to inac-
curacies in the HER-2/neu testing results include preparation,
fixation, and storage of the tissue sections; the antibody or
probe used to detect the HER-2/neu oncogene; the scoring
or result interpretation; the lack of validated methodologies;
the experience of the personnel; and the inter-observer vari-
ability (20, 25, 35). FISH has also been shown to provide reli-
able and accurate information (15, 16, 36). DAKO recom-
mended the use of FISH testing to determine HER-2/neu
status in equivocal circumferences, particularly in all IHC 2+
tumors (24). Although not all laboratories currently have the
equipment necessary to conduct and quantify FISH assays,
their use is becoming more widespread. CISH also has the
advantage of revealing the tissue histopathology, which was
found to be particularly useful when analyzing the metastatic
tumor lesions (3). Metastases often contain only small foci of
cancer cells, which are difficult to find using FISH with dark-
field fluorescence microscopy. Gene amplification detected
by CISH is 91.0% concordant with the results obtained using
FISH (37). In the present study, a poor correlation in IHC 2+
and 3+ tumors has been found compared to the negative
groups (IHC 0 and 1+). Controversy still exists as to whether
cases that show 1+ or 2+ staining. The overall standardiza-
tion for determining and interpreting HER-2/neu by IHC is
still a critical issue with many investigators and clinicians. 
Although CISH is more difficult to apply in routine practice
than IHC, we recommended for clinical application as a com-
plementary test for confirming the IHC results and selecting
the patients for Herceptin treatment. In present study, there
is no relationship between the early recurrence and the HER-
2/neu positive group, but lymph node status was statistically
significant. 
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